Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

PR Newswire
December 12, 2021 — 18:50 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing biotech China Covid-19 Education guangdong healthcare Hong Kong investment medicine Pandemic shenzhen United States University Website World Health Organization

Related News:

Terra Drone, Unifly, and Aloft Technologies Launch UTM Development for AAM Targeting Global Markets

April 25, 2024 — 07:00

Jean-Michel Jarre is world’s first passenger to take off in KleinVision’s flying AirCar

April 24, 2024 — 13:00

Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever

April 24, 2024 — 13:00

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

April 23, 2024 — 20:20

TTC Announces Strategic Expansion into Western Australia with New Perth Office

April 23, 2024 — 04:00

Tantech Holdings Ltd Announces $2.1 Million Private Placement

April 23, 2024 — 03:58

Latham Adds Experienced M&A Partner in Tokyo

April 23, 2024 — 03:15

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

April 22, 2024 — 09:53

Mayur achieves major milestone with US$155 million for Central Lime Project in Papua New Guinea

April 22, 2024 — 09:38